-
Uncomplicated cellulitis, defined as cellulitis without abscess, is most often caused by streptococci.
-
The ECG shown above was obtained from an acutely ill but alert and hemodynamically stable patient. How certain are you that the rhythm is ventricular tachycardia (VT)? Might there be another explanation if the patient in question was a young adult with renal disease and diabetes?
-
The majority of patients with advanced cancer have decisional capacity at the time of their terminal hospitalization but lose that capacity before having an end-of-life discussion.
-
Patients seen in emergency departments (ED) for acute chest pain who are deemed low risk for acute coronary syndrome (ACS) and relatively safe for discharge are often referred to their primary care physician (PCP) for follow-up.
-
-
MRI scan was unable to discriminate between patients with favorable outcome and those with an unfavorable outcome when conducted at 1-year follow-up in patients who were treated for sciatica and disk herniation.
-
This retrospective study of hospitalized patients receiving ceftriaxone found that additional treatment with doxycycline compared to other antibiotics was associated with a lower risk of Clostridium difficile infection.
-
Statin use among cancer patients with diverse malignancies is associated with reduced cancer-related mortality. The mechanism is plausible since statins inhibit cholesterol synthesis, which reduces the pool of compounds necessary in cellular proliferation and maintenance of critical cellular functions, such as membrane integrity, signaling, protein synthesis, and cell cycle progression. Prospective clinical trials are warranted.
-
Omalizumab for Asthma in Real Life; Tenofovir: New Hope for Hepatitis B Patients; H. pylori: Frequency of Recurrence After Successful Eradication
-
The first in a new class of drugs has been approved by the FDA for the treatment of diabetes mellitus. This new class of drugs decreases the renal threshold for glucose excretion by inhibiting the sodium-glucose co-transporter 2 (SGLT2), thus increasing renal clearance of glucose. Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation and marketed by Janssen Pharmaceuticals as Invokana.
